Two Cheers for Evidence-Based Medicine
In recent years, evidence-based medicine has had an important influence on cardiovascular devices, but it's easy to overlook the staying power of subjective judgment. At a session on "What's the Science on Niche Devices?" held during this year's American Heart Association meeting, the cardiologist-audience clearly didn't seem deterred from using certain devices such as DCA and rotoblators, despite equivical or mediocre results in clinical trials.
You may also be interested in...
Device companies have historically kept innovation simple, giving doctors new tools that look and feel very much like what they've used in the past. But what happens when device innovation runs ahead of customers' willingness to adopt new technology?
At this year's Paris Course on Revascularization, much of the discussion turned to drug-eluting stents. An important new clinical trial underscored the technology's value in reducing or eliminating restenosis. But with the product now commercially available in Europe, economic concerns are beginning to be heard loudly.
Over a career that has spanned nearly 40 years, Bob Reiss has built a track record rivaled by few device executives, with senior positions at Sherwood Medical, Alza, Imed, ACS and Interventional Technoloiges. Reiss's most memorable stint: as one of the leaders of ACS, he solved a complex manufacturing problem that helped make angioplasty a common procedure and launched the interventional cardiology revolution. Common to all of Reiss's efforts: the notion that success in medical devices is fundamentally about technology and not, despite the importance of distribution and adoption issues, about marketing.